Why should addiction medicine be an attractive field for young physicians?

Addiction

Volumn 104, Issue 2, 2009, Pages 169-172

  Soyka, Michael ^a,b   Gorelick, David A ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Private Hospital Meiringen   (Switzerland)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction medicine; Addiction psychiatry; Profession; Specialty; Stigma; Training; Treatment

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; METHADONE; NALTREXONE;

ADDICTION; ALCOHOLISM; ARTICLE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DRUG DEPENDENCE; GRADUATE STUDENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; MEDICAL EDUCATION; MEDICAL PROFESSION; MEDICAL PSYCHOLOGY; MEDICAL SPECIALIST; NATIONAL HEALTH SERVICE; PHYSICIAN; PSYCHIATRIST; REIMBURSEMENT; STIGMA; SUBSTANCE ABUSE;

CAREER CHOICE; EDUCATION, MEDICAL; HUMANS; PSYCHIATRY; SUBSTANCE-RELATED DISORDERS;

EID: 58349122300     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02330.x     Document Type: Article

References (26)

1. O'Brien C. P., Volkow N., Li T. K. What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006 163 : 764 5.
2. Erickson C., Wilcox R. Please, not 'addiction' in DSM-V. Am J Psychiatry 2006 163 : 2015 16.
3. McLellan A. T., Lewis D. C., O'Brien C. P., Kleber H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000 284 : 1689 95.
4. Lubman D., Jurd S., Baigent M., Krabman P. Putting 'addiction' back into psychiatry: the RANZCP section of addiction psychiatry. Australas Psychiatry 2008 16 : 39 43.
5. Tinsley J. A. Workforce information on addiction psychiatry graduates. Acad Psychiatry 2004 28 : 56 9.
6. Renner J. A. Jr., Hennessy G., Levin F., Waldbaum M., Eld B. APA addiction psychiatry career survey: Residents' narrative responses. Presented at the American Academy of Addiction Psychiatry annual meeting, December 2006.
7. Rosner S., Leucht S., Lehert P., Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008 22 : 11 23.
8. Gorelick D. A., Gardner E. L., Xi Z. X. Agents in development for the management of cocaine abuse. Drugs 2004 64 : 1547 73.
9. McGinnis J. M., Foege W. H. Mortality and morbidity attributable to use of addictive substances in the United States. Proc Assoc Am Physicians 1999 111 : 109 18.
10. Fenoglio P., Parel V., Kopp P. The social cost of alcohol, tobacco and illicit drugs in France, 1997. Eur Addict Res 2003 9 : 18 28.
11. Andlin-Sobocki P., Rehm J. Cost of addiction in Europe. Eur J Neurol 2005 12 : 28 33.
12. Single E., Robson L., Xie X., Rehm J. The economic costs of alcohol, tobacco and illicit drugs in Canada, 1992. Addiction 1998 93 : 991 1006.
13. O'Brien C. P., Gardner E. L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2005 108 : 18 58.
14. Volkow N. D., Fowler J. S., Wang G. J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004 47 : 3 13.
15. Uhl G. R. Molecular genetics of addiction vulnerability. NeuroRx 2006 3 : 295 301.
16. Grant J. E., Brewer J. A., Potenza M. N. The neurobiology of substance and behavioral addictions. CNS Spectr 2006 11 : 924 30.
17. Reuter P. What drug policies cost. Estimating government drug policy expenditures. Addiction 2006 101 : 315 22.
18. Ettner S. L., Huang D., Evans E., Ash D. R., Hardy M., Jourabchi M. et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment 'pay for itself'? Health Serv Res 2006 41 : 192 213.
19. Godfrey C., Stewart D., Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004 99 : 697 707.
20. Soyka M., Apelt S. M., Wittchen H. U. Die unzureichende Beteiligung von Psychiatern an der Substitutionsbehandlung [Insufficient involvement of psychiatrists in substitution treatment]. Nervenarzt 2006 77 : 1368 72.
21. Liu T., Potenza M. N. Problematic internet use: clinical implications. CNS Spectr 2007 12 : 453 66.
22. Dell'Osso B., Altamura A. C., Allen A., Marazziti D., Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 2006 256 : 464 75.
23. Farah M. J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P. et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004 5 : 421 5.
24. Hall W. Feeling 'better than well EMBO Rep 2004 5 : 1105 9.
25. Savulescu J., Sandberg A. Neuroenhancement of love and marriage: the chemicals between us. Neuroethics 2008 1 : 31 44.
26. Chatterjee A. Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Camb Q Healthcare Ethics 2007 16 : 129 37.